Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07725562 VG081821AC Young onset Parkinson disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07725562 clinical trial report covering VG081821AC, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734792 Tirzepatide Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734792 clinical trial report covering Tirzepatide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07742280 Brexpiprazole Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07742280 clinical trial report covering Brexpiprazole, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07736495 Lipoic acid Chemotherapy oral mucositis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07736495 clinical trial report covering Lipoic acid, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07739199 PD-1/VEGF Trispecific Antibody(Harbour) Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739199 clinical trial report covering PD-1/VEGF Trispecific Antibody(Harbour), Phase 2/3, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07739186 PD-1/VEGF Trispecific Antibody(Harbour) Metastatic Non-Squamous Non-Small Cell Lung Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739186 clinical trial report covering PD-1/VEGF Trispecific Antibody(Harbour), Phase 2/3, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07742553 Finasteride Hypogonadism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07742553 clinical trial report covering Finasteride, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07725484 Lipoic acid Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07725484 clinical trial report covering Lipoic acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07723911 Blinatumomab CD19-positive B-cell acute lymphoblastic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07723911 clinical trial report covering Blinatumomab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128985 Albumin-Bound Paclitaxel Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
ChiCTR2600128985 clinical trial report covering Albumin-Bound Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07735117 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07735117 clinical trial report covering Venetoclax, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733765 Ritlecitinib Tosilate Alopecia Areata Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733765 clinical trial report covering Ritlecitinib Tosilate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.